Medical Oncology Department, University Clinic of Respiratory and Allergic Diseases, 4204 Golnik, Slovenia.
Medical Oncology Department, Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia.
Curr Oncol. 2022 Aug 17;29(8):5833-5845. doi: 10.3390/curroncol29080460.
The targeted therapy with tyrosine kinase inhibitors (TKIs) against the epidermal growth factor receptor mutation (EGFRm) in advanced non-small cell lung cancer (NSCLC) changed the treatment paradigm. REFLECT study (NCT04031898) explored / testing and treatment patterns in EGFRm NSCLC patients receiving first- or second-generation (1G/2G) EGFR TKIs as front-line (1L) in eight countries. Pooled data from Central Eastern Europe (CEE) countries from this study (Bulgaria, Poland, Romania, Slovenia) are presented here. This physician-led chart review study was conducted in patients with confirmed-EGFRm NSCLC initiating 1L 1G/2G EGFR TKIs between 2015-2018. The CEE cohort included 389 patients receiving 1L erlotinib (37%), afatinib (34%), and gefitinib (29%). Overall, 320 (82%) patients discontinued 1L, and 298 (77%) progression events were registered. Median progression free survival on 1L TKIs was 14.0 (95% CI: 12.6-15.6) months. Median overall survival from 1L start was 26.6 (95% CI: 24.1-29.0) months. Attrition rate between 1L and next line was 30%. Among patients with 1L progression, 200 (67%) were tested for and 58% were positive. This first CEE analysis of treatments and outcomes in EGFRm NSCLC patients highlights the importance of using the most efficacious therapies currently available in 1L to reduce attrition and improve patient outcomes.
表皮生长因子受体突变（EGFRm）的酪氨酸激酶抑制剂（TKIs）靶向治疗改变了晚期非小细胞肺癌（NSCLC）的治疗模式。REFLECT 研究（NCT04031898）探索了在 8 个国家接受第一代或第二代（1G/2G）EGFR TKI 作为一线（1L）治疗的 EGFRm NSCLC 患者的检测和治疗模式。本文呈现了该研究中来自中东欧（CEE）国家（保加利亚、波兰、罗马尼亚、斯洛文尼亚）的汇总数据。这项由医生主导的图表回顾性研究在 2015 年至 2018 年间，对确诊为 EGFRm NSCLC 并开始接受 1L 1G/2G EGFR TKI 治疗的患者进行。CEE 队列包括 389 例接受 1L 厄洛替尼（37%）、阿法替尼（34%）和吉非替尼（29%）治疗的患者。总体而言，320 例（82%）患者停止了 1L 治疗，298 例（77%）发生了进展事件。1L TKI 的中位无进展生存期为 14.0（95%CI：12.6-15.6）个月。从 1L 开始的中位总生存期为 26.6（95%CI：24.1-29.0）个月。1L 和下一线之间的失访率为 30%。在 1L 进展的患者中，200 例（67%）接受了检测，58%呈阳性。这是对 EGFRm NSCLC 患者治疗和结局的首次 CEE 分析，突出了在 1L 中使用最有效的治疗方法的重要性，以减少失访并改善患者结局。
